In this regard, a study evaluated the relationship between the CTC-positive status of patients with mRCC and the expression of blood tumor markers, namely cytokeratin 19 (CK19), endoglin (CD105) and CD146 [89]. This evidence concerns the gene KRT19 and neoplasm.